文献速递核素与放射性配体治疗肿瘤 PET/CT

转移性神经内分泌肿瘤患者接受肽受体放射性核素治疗时68Ga-DOTA-JR11 PET/CT与剂量学177Lu-satoreotide tetraxetan SPECT/CT的比较

Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-05-06

这项前瞻性临床试验纳入20例转移性神经内分泌肿瘤患者,比较68Ga-DOTA-JR11 PET/CT与177Lu-satoreotide tetraxetan SPECT/CT的病灶摄取。共分析95个病灶,PET/CT与SPECT/CT的SUV及肿瘤/正常组织比值显著相关但相关性中等(Pearson r 0.3–0.7)。68Ga-DOTA-JR11 PET可用于患者选择和PRRT,PET低摄取不应排除治疗。

要点

  • 68Ga-DOTA-JR11 PET/CT与177Lu-satoreotide tetraxetan SPECT/CT的SUV及肿瘤/正常组织比值显著相关,但相关性中等(r 0.3–0.7)。
  • 所有患者中177Lu-satoreotide tetraxetan与68Ga-DOTA-JR11的病灶SUVpeak摄取比值均较高,即使PET低摄取(SUVpeak≤10)者比值仍达8.0±5.2。
  • 68Ga-DOTA-JR11 PET可用于患者选择和PRRT,PET低肿瘤摄取不应排除177Lu-satoreotide tetraxetan治疗。

核心结论

  • 68Ga-DOTA-JR11 PET可用于患者选择和PRRT,PET低肿瘤摄取不应排除177Lu-satoreotide tetraxetan治疗。
  • 单时间点SPECT/CT用于吸收剂量计算可简化剂量学方案、节省成本并提高患者便利性。

研究设计与样本

  • 作为一项前瞻性临床试验的一部分,20例转移性神经内分泌肿瘤患者接受了68Ga-DOTA-JR11 PET/CT和177Lu-satoreotide tetraxetan系列显像。
  • 采用线性回归分析和Pearson相关比较PET/CT与SPECT/CT的病灶摄取参数及177Lu-satoreotide tetraxetan病灶吸收剂量。

主要发现

  • 共分析95个病灶的68Ga-DOTA-JR11 PET/CT和177Lu-satoreotide tetraxetan SPECT/CT。
  • PET/CT与SPECT/CT的SUV和肿瘤/正常组织比值显著相关(p<0.01),但Pearson相关系数范围为0.3至0.7,相关性中等。
  • 观察到患者内病灶相关性存在变异。
  • 所有患者中177Lu-satoreotide tetraxetan与68Ga-DOTA-JR11的病灶SUVpeak摄取比值均较高;即使68Ga-DOTA-JR11 PET/CT低摄取(SUVpeak≤10)者,比值仍为8.0±5.2。
  • 68Ga-DOTA-JR11的SUVpeak与预测的177Lu-satoreotide tetraxetan吸收剂量(n=42)相关性中等(r=0.5,p<0.01);177Lu-satoreotide tetraxetan的SUVpeak与预测的177Lu-satoreotide tetraxetan吸收剂量相关性极好(r=0.9,p<0.0001)。

关键数值与推荐

  • PET/CT与SPECT/CT的SUV和肿瘤/正常组织比值显著相关(p<0.01),Pearson相关系数0.3–0.7。
  • 68Ga-DOTA-JR11 PET/CT低摄取(SUVpeak≤10)患者中,177Lu-satoreotide tetraxetan与68Ga-DOTA-JR11的病灶SUVpeak摄取比值为8.0±5.2。
  • 68Ga-DOTA-JR11 SUVpeak与预测177Lu-satoreotide tetraxetan吸收剂量相关性中等(n=42,r=0.5,p<0.01)。
  • 177Lu-satoreotide tetraxetan SUVpeak与预测177Lu-satoreotide tetraxetan吸收剂量相关性极好(r=0.9,p<0.0001)。

临床怎么用

  • 作者结论认为68Ga-DOTA-JR11 PET可用于患者选择和PRRT,PET低肿瘤摄取不应排除患者接受177Lu-satoreotide tetraxetan治疗。
  • 作者认为单时间点SPECT/CT用于吸收剂量计算可简化剂量学方案、节省成本并提高患者便利性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Paired imaging/therapy with radiolabeled somatostatin receptor (SSTR) antagonists is a novel approach in neuroendocrine tumors (NETs). The aim of this study was to compare tumor uptake of 68Ga-DOTA-JR11 and 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) in patients with NETs. METHODS: As part of a prospective clinical trial, 20 patients with metastatic NETs underwent 68Ga-DOTA-JR11 PET/CT and serial imaging with 177Lu-satoreotide tetraxetan. PET/CT and SPECT/CT parameters for lesion uptake and absorbed dose of 177Lu-satoreotide tetraxetan in lesions were compared using linear regression analysis and Pearson correlation. RESULTS: A total of 95 lesions were analyzed on 68Ga-DOTA-JR11 PET/CT and 177Lu-satoreotide tetraxetan SPECT/CT. SUVs and tumor-to-normal-tissue ratios on PET/CT and SPECT/CT were significantly correlated (p < 0.01), but the degree of correlation was modest with Pearson correlation coefficients ranging from 0.3 to 0.7. Variation in intrapatient lesional correlation was observed. Nevertheless, in all patients, the lesion SUVpeak uptake ratio for 177Lu-satoreotide tetraxetan vs. 68Ga-DOTA-JR11 was high; even in those with low uptake on 68Ga-DOTA-JR11 PET/CT (SUVpeak ≤ 10), a ratio of 8.0 ± 5.2 was noted. Correlation of SUVpeak of 68Ga-DOTA-JR11 with projected 177Lu-satoreotide tetratexan-absorbed dose (n = 42) was modest (r = 0.5, p < 0.01), while excellent correlation of SUVpeak of 177Lu-satoreotide tetraxetan with projected 177Lu-satoreotide tetraxetan-absorbed dose was noted (r = 0.9, p < 0.0001). CONCLUSION: Our study shows that 68Ga-DOTA-JR11 PET can be used for patient selection and PRRT and that low tumor uptake on PET should not preclude patients from treatment with 177Lu-satoreotide tetraxetan. The ability to use single time-point SPECT/CT for absorbed dose calculations could facilitate dosimetry regimens, save costs, and improve patient convenience.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Krebs S, O'Donoghue JA, Biegel E, et al. Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2020. PMID: 32378020. doi:10.1007/s00259-020-04832-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。